Double-Unit Cord Blood Transplantation (DCBT) for Acute Leukemia: High Disease-Free Survival in Adults and Children with Comparable Survival in European and Minority Patients  by Barker, J.N. et al.
S270 Poster Session IUnivariate analysis of the association between patient/graft charac-
teristics and grade III-IV aGVHD showed the only significant factor
associated with a higher severe aGVHD incidence was age 0-15
years. Multivariate Cox regression analysis was performed (Table).
Younger age was independently associated with a higher severe
aGVHD incidence whereas better engrafting unit-recipient 8-9/10
HLA-allele match was protective. There was a trend toward better
unit-unit HLA-match being associated with worse aGVHD, but,
surprisingly, total infused TNC/kg had no relationship. The 2-
year PFS of 72% (95%CI:51-94) in children was higher than the
56% (95%CI:45-66) in adults despite their greater incidence of se-
vere aGVHD. We conclude that aGVHD after DCBT is common,
predominantly affects the gut, has a high treatment response, chil-
dren are at a higher risk for severe disease, and late GVHD fre-
quently has acute features. While survival is promising, improved
prophylaxis and treatment are needed. A possible approach to reduce
aGVHD in pediatric DCBT recipients with adequate CB unit doses
would be to prioritize high resolution HLA-match. Moreover, our
data does not currently support an upper limit of infused TNC/kg
in DCBT recipients. Further investigation of the biology underlying
these unique observations should be a priority.
Table. Multivariate Analysis
Cumulative
Characteristic Incidence (95% CI) Hazard Ratio P ValueAge (years)
0-15 (n 5 18) 41% (17-65) 2.6 (1.0-6.4) 0.042
$ 16 (n 5 90) 20% (12 -29) Reference -
Engrafting Unit-Recipient 10 Allele HLA-Match
2-7/10 (n 5 83) 27% (17-37) Reference -
8-9/10 (n 5 25) 12% (0-25) 0.3 (0.1-1.0) 0.053
Unit-Unit 10 Allele HLA-Match
0-5/10 (n 5 59) 20% (9-29) Reference -
6-10/10 (n 5 49) 29% (16-42) 2.2 (1.0-5.0) 0.062
Total TNC x107/kg
< 5.0 (n 5 68) 20% (10-29) Reference -
$ 5.0 (n 5 40) 31% (16-46) 1.2 (0.5-2.8) 0.617179
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As DCBT may improve engraftment and protect against relapse,
we have adopted DCBT for children and adults with high-risk acute
leukemia, myelodysplasia (MDS), and myeloproliferative diseases
(MPD). We analyzed DFS in 75 DCBT recipients with acute leuke-
mia in morphologic remission or aplasia (n 5 69), and MDS/MPD
with # 5% blasts (n 5 6) transplanted 10/2005-4/2011. Children
(n5 23, 43% AML, 52% ALL, and 4%MDS/MPD) were a median
of 9 years (range 0.9-15) and 37 kg (range 7-72), 30% were
European, and 26% were CMV sero-positive. All received high-
dose conditioning. Pediatric grafts had a median infused TNC x
107/kg of 3.3 (larger unit) and 2.6 (smaller unit), and 2% of units
were 6/6 HLA-A,-B antigen,-DRB1 allele matched, 63% 5/6, and
35% 4/6. Adults (n 5 52, 63% AML, 27% ALL, and 10% MDS/
MPD) were a median of 41 years (range 16-69) and 69 kg (range
47-105), 48% were European, and 69% were CMV sero-positive.
Fifty percent received high-dose and 50% reduced intensity condi-
tioning. Their units had median infused TNC/kg of 2.7 and 1.9,
and 3%were 6/6HLA-matched, 47% 5/6, and 50% 4/6. All patients
received calcineurin-inhibitor/ mycophenolate mofetil immunosup-
pression. Sustained neutrophil engraftment was seen in 91% of chil-
dren and 94% of adults at medians of 20 and 26 days, respectively.
Day 180 grade II-IV acute GVHD incidence was 44% in childrenand 58% in adults. Day 100 transplant-related mortality was 9% in
children and 19% in adults. 2-year relapse incidence was 9% in chil-
dren and 6% in adults. With a median survivor follow-up of 26
months (range 4-70), 2-year DFS was 78% in children and 64% in
adults. Univariate analysis of variables potentially influencing 2-
year DFS is shown (Table). There were no differences in 2-year
DFS according to ancestry, remission status, conditioning intensity,
engrafting unit infused TNC dose/kg, or engrafting unit-recipient
HLA-match (4-6/6 or 10 allele). However, CMV seronegative pa-
tients had a higher 2-year DFS (85% vs 55%, p 5 0.018). Multivar-
iate analysis revealed CMV serostatus was a DFS predictor
independent of patient age. We have previously shown that DCBT
extends transplant access to minorities. We now demonstrate that
DCBT can achieve high and comparable DFS in European and
non-European pediatric and adult leukemia patients. Our findings
support DCBT as an immediate alternative for high-risk acute leu-
kemia patients without rapidly available unrelated donors, especially
given the very low relapse incidence.
Table.
Comparison 2-Year DFS P ValueAncestry Europeans (n 5 32) 67% 0.884
Non-Europeans (n 5 43) 69%Remission CR1 (n 5 41) 69% 0.663
Status All others (n 5 34) 67%
Conditioning High-dose (n 5 49) 71% 0.687
Intensity Reduced intensity (n 5 26) 62%
Recipient CMV CMV+ (n 5 42) 55% 0.018
Sero-status CMV- (n 5 33) 85%
Engrafting Unit < 3.0 x 107/kg (n 5 56) 65% 0.307
Infused TNC Dose $ 3.0 x 107/kg (n 5 19) 77%
Engrafting Unit-recipient 4/6 (n 5 30) 72% 0.596
Match (4-6/6) 5-6/6 (n 5 45) 65%
Engrafting Unit-recipient 2-6/10 (n 5 41) 64% 0.418
Match (10 allele) 7-9/10 (n 5 34) 73%180
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Background: Patients searching the Be The Match Registry are
evaluated for HLA matching with over 9.5 million donors, 88% with
a minimum of HLA-A/B/DRB1 typing and 12% with HLA-A/B
only (i.e., noDRB1) typing. Patients with no potential 6/6 HLA allele
matched donors present a challenging search for which transplant
centers may consider DRB1 typing of A/B only donors. Selection of
A/B only donor typing varies by center, so a study was performed to
evaluate the utility of this practice in identifying A/B/DRB1 (6/6)
matched donors given the size of the Be The Match Registry.
Methods:We identified 180 new patient searches with no potential
6/6 HLA allele matched donors, reviewed the search results, and
typed DRB1 on a total of 2,976 A/B only donors with stored DNA
samples. The median number of tested A/B only donors per patient
was 4, ranging from 1 to 231. Donor DRB1 typing results were com-
pared to the corresponding patient’s DRB1 alleles to confirm high
resolution match status.
Results: Of 2,976 donors typed for 180 patients, two donors
matched their respective patient’s DRB1 typing. One DRB1
matched donor became a 10/10 match to the patient whose search
previously contained no 6/6 potential matches. This donor carried
an A/B/DRB1 phenotype that had not previously been identified his-
torically in a Be The Match Registry donor.
Conclusions: These results show very limited benefit to HLA-A/B
only donor testing for the patients considered in this study, with only
two patients identifying a DRB1 matched donor. With most A/B
only donors typed by serology, additional mismatches are possible.
Since only donors with stored DNA samples were tested (26% of
the total A/B only donors), additional DRB1 matches may have
been identified if every A/B only donor for each patient were tested.
Study patients represented challenging searches with no potential
